Rexahn Pharmaceuticals

[Rexahn Pharmaceuticals @RexahnPharma]

Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China https://t.co/WVWXenq7js

[Rexahn Pharmaceuticals @RexahnPharma]

Rexahn welcomes Lara S. Sullivan, M.D. to its board of directors. https://t.co/WYf18WMEL4

[Rexahn Pharmaceuticals @RexahnPharma]

Learn more about how @RexahnPharma approaches developing cancer drugs in the article "Solutions in... Drug Development" via @medicine_maker: https://t.co/VXaySj4POd

[Rexahn Pharmaceuticals @RexahnPharma]

Rexahn recently presented updated interim data from its Phase 2a trial of RX-3117 in advanced bladder cancer: https://t.co/CLT4j0q2GF

[Rexahn Pharmaceuticals @RexahnPharma]

Read the @DGIwire story “Taking Better Aim at Tumors" featuring @RexahnPharma: https://t.co/vl73eFA8Q3

[Rexahn Pharmaceuticals @RexahnPharma]

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types https://t.co/4615dGM4zo

[Rexahn Pharmaceuticals @RexahnPharma]

Check out the @DGIwire story “What’s Next in the Fight Against Pancreatic Cancer?" featuring @RexahnPharma: https://t.co/JKP4ogBvt4

[Rexahn Pharmaceuticals @RexahnPharma]

Read the @DGIwire story “For Cancer Immunotherapy Patients, a ‘One-Two Punch’ Could Hold Promise" featuring @RexahnPharma: https://t.co/KI0cLsAN3H

[Rexahn Pharmaceuticals @RexahnPharma]

Learn more about combination treatments studied by @RexahnPharma for #immunotherapy and #chemotherapy in the article "Small molecules could have big benefits in the battle against cancers" via @DrugTargetRev: https://t.co/Ib40psiQtr

[Rexahn Pharmaceuticals @RexahnPharma]

@RexahnPharma CEO contributes to @wpahospitalnews "Small and Selective: Tumor-Destroying Compounds Take Shape": https://t.co/a71hXaN8x8

[Rexahn Pharmaceuticals @RexahnPharma]

Learn more about what @RexahnPharma is saying about combination treatments for cancer in the article "Giving Immunotherapy and Chemotherapy a Molecular Boost" via @DGIwire: https://t.co/YYhd6cSYFv

[Rexahn Pharmaceuticals @RexahnPharma]

Read "Bladder Cancer: 3 Things to Know" via @DGIwire to learn about a compound being studied by @RexahnPharma for advanced bladder cancer: https://t.co/Pf5XMH5xuE

[Washington Business Journal @WBJonline]

Rockville biotech restructures with job cuts, changes to pipeline under new leadership https://t.co/FJDznXkt8w

[Rexahn Pharmaceuticals @RexahnPharma]

Rexahn is streamlining its operations to enable more efficient development of its clinical-stage oncology pipeline. https://t.co/vrLLHg7tmp

[Rexahn Pharmaceuticals @RexahnPharma]

@RexahnPharma CEO discusses combination treatments for #breastcancer in the @DGIwire article "What’s Best for Breast Cancer: The Possibilities of Enhancing Immunotherapy": https://t.co/dY5FF7M3x4 #immunotherapy

[Rexahn Pharmaceuticals @RexahnPharma]

Rexahn is pleased to welcome Gil Price to its board of directors. https://t.co/fMVxcCuend

[Rexahn Pharmaceuticals @RexahnPharma]

@DGIwire published the article "A Nobel-Worthy Advance: Battling Cancer by Retooling the Body’s Immune Response" featuring @RexahnPharma: https://t.co/P1R3l2Fh4f

[Washington Business Journal @WBJonline]

‘Not business as usual’: Rockville biotech’s new CEO wants to turn things around https://t.co/dM6Hg8wxEh

[Rexahn Pharmaceuticals @RexahnPharma]

We thank Peter Suzdak for his leadership of the company over the past six years. We value Peter’s contributions and wish him well in the future. https://t.co/zVB44JOoZ4

[Rexahn Pharmaceuticals @RexahnPharma]

Learn more about @RexahnPharma and @Merck collaboration with #Keytruda in the article published by @InPharmaTechno: https://t.co/MAD0r0VR3E